Sugi Predict

Sugi Predict / Compounds / SCHEMBL486127

SCHEMBL486127

SCHEMBL486127

ClCc1nc2ccc(Cl)cc2o1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CG P48736 1/20 0.58
▸ SOS1 Q07889 1/20 0.56
▸ PSMB8 P28062 1/20 0.53
▸ PSMB5 P28074 1/20 0.53
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ MAPT P10636 6/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ S1PR3 Q99500 2/20 0.46
▸ XDH P47989 2/20 0.43
▸ NLRP3 Q96P20 2/20 0.43
▸ SNCA P37840 1/20 0.43
▸ FBP1 P09467 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ LMNA P02545 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ RAB9A P51151 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4285418 0.85 MEN1 (0.64) SOS1PSMB8MEN1KMT2AMAPT
SCHEMBL30612632 0.85 MEN1 (0.64) SOS1PSMB8MEN1KMT2AMAPT
SCHEMBL17221714 0.84 PIK3CG (0.61) PIK3CGSOS1PSMB8PSMB5MEN1
SCHEMBL11934535 0.84 PIK3CG (0.56) PIK3CGSOS1PSMB8PSMB5MEN1
SCHEMBL17221435 0.84 PIK3CG (0.56) PIK3CGSOS1PSMB8PSMB5MEN1
SCHEMBL16006862 0.84 PIK3CG (0.56) PIK3CGSOS1PSMB8PSMB5MEN1
SCHEMBL7899514 0.81 LOXL2 (0.60) PIK3CGSOS1PSMB8PSMB5MEN1
SCHEMBL23932508 0.80 MAPT (0.46) PIK3CGSOS1MEN1KMT2AMAPT
SCHEMBL4288555 0.80 KDM4E (0.74) MEN1KMT2AMAPTKDM4EXDH
SCHEMBL9199893 0.80 ESR1 (0.53) MAPTKDM4ELMNAALOX15RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119775261-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2025-04-08 — — CN disclosed
CN-119775223-A Benzoxazole derivative containing dithioacetal unit, and preparation method and application thereof 贵州大学 2025-04-08 — — CN disclosed
CN-115427404-B Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2024-12-13 — — CN disclosed
EP-4139291-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF Anima Biotech Inc. (US) 2023-03-01 — — EP disclosed
CN-115427404-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2022-12-02 — — CN disclosed
WO-2022053541-A1 COMPOUNDS FOR USE AS APPETITE SUPPRESSANT ERACAL THERAPEUTICS LTD. (CH) 2022-03-17 — — WO disclosed
WO-2021216665-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-10-28 — — WO disclosed
US-8283479-B2 CXCR2 inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2012-10-09 — — US disclosed
US-8283479-B2 CXCR2 inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2012-10-09 — — US disclosed
US-8283479-B2 CXCR2 inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2012-10-09 — — US disclosed
US-7919628-B2 2-[(1-Benzyloxy-naphthalene-2-carbonyl)-amino]-2-methyl-propionic acid; inhibitors of chemokine receptors; treatment or prophylaxis of acute and chronic inflammatory diseases such as atherosclerosis, ischemic or reperfusion injuries, chronic obstructive pulmonary disease, asthma, rheumatoid arthritis SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-04-05 — — US disclosed
US-7919628-B2 2-[(1-Benzyloxy-naphthalene-2-carbonyl)-amino]-2-methyl-propionic acid; inhibitors of chemokine receptors; treatment or prophylaxis of acute and chronic inflammatory diseases such as atherosclerosis, ischemic or reperfusion injuries, chronic obstructive pulmonary disease, asthma, rheumatoid arthritis SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-04-05 — — US disclosed
US-7919628-B2 2-[(1-Benzyloxy-naphthalene-2-carbonyl)-amino]-2-methyl-propionic acid; inhibitors of chemokine receptors; treatment or prophylaxis of acute and chronic inflammatory diseases such as atherosclerosis, ischemic or reperfusion injuries, chronic obstructive pulmonary disease, asthma, rheumatoid arthritis SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-04-05 — — US disclosed
WO-2009153536-A1 1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2009-12-23 — — WO disclosed
WO-2009153536-A1 1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2009-12-23 — — WO disclosed
US-20080090854-A1 CXCR2 INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-17 — — US disclosed
US-20080090854-A1 CXCR2 INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-17 — — US disclosed
US-20080090854-A1 CXCR2 INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-17 — — US disclosed
EP-1836158-A1 FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION Sanofi-Aventis Deutschland GmbH (DE) 2007-09-26 — — EP disclosed
WO-2006069656-A1 FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2006-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090854-A1 CXCR2 INHIBITORS CXCR2, CXCR1, CXCR4 PIK3CG 2925/4885SOS1 1640/4885PSMB8 4166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.